PD-1 Modulating Compounds for T Cell Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for modulating immune responses, particularly in cancer and infectious diseases, face challenges in effectively activating T cells due to the inhibitory PD-1/PD-L pathway, which suppresses T cell proliferation and activation.
Innovation Solution
Development of pharmaceutical compositions comprising specific PD-1 modulating compounds that bind to the PD-1 receptor, either blocking inhibitory signals or promoting activating signals, thereby enhancing T cell activation, proliferation, and cytokine production, and overcoming immune tolerance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PD-1/PD-L pathway is utilized for immune regulation, then immune tolerance is maintained, but T cell activation and proliferation are suppressed
Solution Approach 1:
The patent converts the inhibitory PD-1 signal into an activating signal by using compounds that bind to PD-1 and trigger alternative signaling pathways. Instead of simply blocking the inhibitory interaction, the invention exploits the PD-1 receptor itself to deliver activating signals, transforming a harmful inhibitory pathway into a beneficial activating pathway for T cell responses
Solution Approach 2:
The patent changes the signaling parameter of PD-1 from inhibitory to activating by introducing small molecule compounds that alter the conformational state or downstream signaling of the PD-1 receptor. These compounds modify the functional output of PD-1 engagement, switching it from delivering negative signals to delivering positive activating signals that promote T cell proliferation and cytokine production
2Productivity
If anti-PD-1 antibodies are used to block inhibitory signals, then T cell activation is enhanced, but additional activating signals are required
Solution Approach 1:
The patent merges the blocking function and activating function into a single compound-action. The small molecule compounds simultaneously block inhibitory PD-1/PD-L interactions and trigger activating signals through PD-1, combining multiple functions that would otherwise require separate agents into one unified therapeutic approach
Solution Approach 2:
The patent creates multi-functional compounds that can both block inhibitory signals and provide activating signals through a single mechanism of PD-1 engagement. This universal approach eliminates the need for multiple separate signals or agents, simplifying the therapeutic regimen while maintaining robust T cell activation
Data Source
Figure 1A~1D
Figure 1E~1H
Figure 1I~1L
AI summary
Several compounds have been discovered that modulate signal transduction through the PD-1 receptor. In certain embodiments, the compounds promote or induce an activating signal through the PD-1 receptor that activates a T cell. The compounds can bind to PD-1 and inhibit or prevent ligands from binding to PD-1 and thereby suppress inhibitory signal transduction through the PD-1 receptor.